tiprankstipranks
Advertisement
Advertisement
Buy Rating Reaffirmed as Vanda’s Regulatory Catalysts Support Unchanged $21 Price Target
PremiumRatingsBuy Rating Reaffirmed as Vanda’s Regulatory Catalysts Support Unchanged $21 Price Target
1M ago
Vanda Pharmaceuticals announces Rare Pediatric Disease Designation for VCA-894A
Premium
The Fly
Vanda Pharmaceuticals announces Rare Pediatric Disease Designation for VCA-894A
1M ago
Vanda Shareholders Approve Directors, Auditor and Compensation Plans
Premium
Company Announcements
Vanda Shareholders Approve Directors, Auditor and Compensation Plans
2M ago
Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M
PremiumThe FlyVanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M
3M ago
Vanda Pharmaceuticals announces U.S. commercial availability of Nereus
Premium
The Fly
Vanda Pharmaceuticals announces U.S. commercial availability of Nereus
3M ago
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
Premium
The Fly
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
3M ago
Geron appoints Timothy Williams as chief legal officer
PremiumThe FlyGeron appoints Timothy Williams as chief legal officer
4M ago
Vanda calls on FDA to remove proposal extending drug review timelines
Premium
The Fly
Vanda calls on FDA to remove proposal extending drug review timelines
4M ago
Vanda Pharmaceuticals: Undervalued GLP-1 Adjunct Opportunity Driven by Tradipitant’s Pivotal Thetis Trial
Premium
Ratings
Vanda Pharmaceuticals: Undervalued GLP-1 Adjunct Opportunity Driven by Tradipitant’s Pivotal Thetis Trial
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100